<DOC>
	<DOCNO>NCT01823172</DOCNO>
	<brief_summary>The investigator plan study ability identify lymph node beyond sentinel lymph node may harbor cancer use methylene blue dye .</brief_summary>
	<brief_title>Second Echelon Node Study With Methylene Blue</brief_title>
	<detailed_description>After lymphatic mapping SLN Tc-99 sulfur colloid , second-echelon lymphatic mapping perform methylene blue dye inject SLN 0.05-0.10 cc non dilute methylene blue trace via efferent lymphatic channel second echelon lymph node ( Figure 1 ) . For initial patient 27 gauge needle 3cc syringe utilized modify study 30 gauge needle 1cc syringe . The blue efferent lymphatic trace minimal spread surround tissue visualize drainage next lymph node ( ) . A second echelon lymph node consider blue lymph node lymph node blue dye lead directly . The number second echelon lymph node record . The second-echelon lymph node ( ) remove .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Methylene Blue</mesh_term>
	<criteria>Histologically confirm primary cutaneous melanoma locate extremity trunk Patients clinically stage III melanoma Histologically confirm invasive ductal lobular carcinoma Patient undergoing surgical treatment breast primary sentinel lymph node biopsy clinically node negative Melanoma locate head neck , uveal mucosal Previous surgery radiation near sentinel lymph node biopsy nodal basin Preoperative biopsy proven regional lymph node involvement Failure lymphatic mapping radioactive colloid Women pregnant nursing Prior ipsilateral axillary surgery radiation Inflammatory breast cancer No lymph node identify ipsilateral breast pathologic review mastectomy specimen Stage IV breast cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>melanoma</keyword>
	<keyword>sentinel lymph node biopsy</keyword>
	<keyword>lymphadenectomy</keyword>
</DOC>